Clinical trials: Skin Toxicity
Non-small Cell Lung Cancer, Esophageal Cancer
Radiation-induced Toxicity of the Heart
Late side effects in radio(chemo)therapy [R(CH)T] pose a critical limitation to patients' overall survival and quality of life. Even though toxicities of the heart are highly relevant for patients with cancer in the thoracic…
- Conditions
- Non-small Cell Lung Cancer, Esophageal Cancer, Breast Cancer Female
- Trial name
- CorTox (NCT06986291)
- Testing
- Imaging and biomarkers
- Where
- Germany
- Volunteers
- 325 people
- Sponsor
- Technische Universität Dresden
Head and Neck Neoplasms
Radiotherapy Related Skin Toxicity: Mepitel® vs. Standard Care in Patients With Locally Advanced Head-and-Neck Cancer
The aim for the present study named RAREST (RAdiotherapy RElated Skin Toxicity) is to compare the new dressing with the standard skin care.
- Trial name
- RAREST-01 (NCT03047174)
- Testing
- Mepitel® Film, Standard Care
- Where
- 2 sites in Germany
- Volunteers
- 57 people
- Sponsor
- University Hospital Schleswig-Holstein
Melanoma
LATe TreatmENT Related Toxicity in Melanoma (LATENT)
Recent improvements in advanced melanoma treatment with immunotherapy have dramatically improved patient survival. Longer survival however has come at a cost of toxicity.
- Trial name
- LATENT (NCT06414343)
- Testing
- Observational - no intervention
- Where
- United Kingdom
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Royal Marsden NHS Foundation Trust
Cardiotoxicity, Risk Factor, Cardiovascular
Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab
Investigators will evaluate the safety, tolerability, and feasibility of a risk-guided cardioprotective treatment strategy with carvedilol, as compared to usual care, in breast cancer patients undergoing treatment with…
- Conditions
- Cardiotoxicity, Risk Factor, Cardiovascular, Toxicity Due to Chemotherapy, Breast Cancer
- Trial name
- CCTGuide Pilot (NCT04023110)
- Testing
- Carvedilol
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Advanced Solid Tumor, Metastatic Breast Cancer
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
This is a multicenter, open label, nonrandomized, sequential dose escalation/dose ranging, multiple dose study designed to evaluate the safety, toxicity, and PK as well as preliminary efficacy of BTX-A51 alone and in combination…
- Trial name
- NCT04872166
- Testing
- BTX-A51
- Where
- 6 sites in United States
- Volunteers
- 112 people
- Sponsor
- Edgewood Oncology Inc.
Colorectal Cancer Metastatic, Skin Toxicity
Pre-emptive Cycline Treatment on Cetuximab Induced Skin Toxicity in Colorectal Cancer
The aim of this study is to test the role of cycline in the prevention of acne-like skin rash in metastatic colorectal patients treated with Cetuximab and intensified FOLFIRI.
- Trial name
- SKINUX (NCT01317433)
- Testing
- Doxycycline, Cetuximab
- Where
- 5 sites in France
- Volunteers
- 25 people
- Sponsor
- Institut Cancerologie de l'Ouest
Metastatic Colorectal Cancer, Skin Rash
Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy
A comparison of prophylactic treatment with reactive treatment for skin toxicity observed in patients with metastatic colorectal cancer (mCRC) who are receiving second-line irinotecan-based chemotherapy concomitantly with…
- Conditions
- Metastatic Colorectal Cancer, Skin Rash, Skin Toxicities, Colon Cancer
- Trial name
- STEPP (NCT00332163)
- Testing
- Panitumumab, Irinotecan, FOLFIRI
- Volunteers
- 95 people
- Sponsor
- Amgen
Metastatic Colorectal Cancer, Cetuximab
Crisaborole Ointment for Skin Toxicity Induced by Cetuximab
This is a prospective, single-arm, phase II clinical trial that will enroll metastatic colorectal cancer patients with Cetuximab-Related Skin Toxicity, who will receive crisaborole ointment twice daily.
- Conditions
- Metastatic Colorectal Cancer, Cetuximab, Skin Toxicity
- Trial name
- COSTIC (NCT06118047)
- Testing
- Crisaborole Ointment, Cetuximab
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Sun Yat-sen University
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
PRISM Trial: Partial Breast Versus Whole Breast Radiation in Early Breast Cancer
Breast-conserving surgery followed by radiotherapy is a standard treatment for women with early-stage breast cancer. Whole breast irradiation (WBI) is the current standard approach, but partial breast irradiation (PBI), which…
- Trial name
- PRISM (NCT07811635)
- Testing
- Ultra-Hypofractionated Partial Breast Irradiation, Ultra-Hypofractionated Whole Breast Irradiation
- Where
- 3 sites in Pakistan, Saudi Arabia and 1 more
- Volunteers
- 100 people
- Sponsor
- Jinnah Postgraduate Medical Centre
Glucocorticoids Toxicity, Iatrogenic Effect
Effects of Glucocortioids in Human Skeletal Muscle, Adipose Tissue and Skin
BACKGROUND: A notorious and dreaded adverse effect of glucocorticoids (GC) is redistribution of muscle and fat mass towards muscle wasting and visceral obesity.
- Trial name
- FUSION (NCT06145126)
- Testing
- Prednisolone
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Breast Neoplasms, Chemotherapeutic Toxicity
App for Adverse Events to Oral Chemotherapy - Pilot Study
In recent years, the treatment paradigm for hormone receptor positive, HER2-negative disease has shifted from "chemotherapy for visceral disease" and "hormone therapy for bone disease" to "chemotherapy only for visceral crises or…
- Trial name
- NCT05743686
- Testing
- Application
- Where
- Canada
- Volunteers
- 28 people
- Sponsor
- Julie Lemieux
Breast Cancer
Breast Radiotherapy Audio Visual Enhancement for Sparing the Heart
This study investigates the Breathe Well device to test whether it is superior to the existing treatment standard of the Varian Realtime Position Management (RPM) system in assisting patients with deep inspiration breath hold.
- Trial name
- BRAVEHeart (NCT02881203)
- Testing
- Breathe Well, RPM
- Where
- Australia
- Volunteers
- 45 people
- Sponsor
- University of Sydney
Glomerulonephritis, Lupus Nephritis
Cyclophosphamide and Fludarabine to Treat Lupus Nephritis
This study will test the safety and effectiveness of combination therapy with cyclophosphamide (Cytoxan) and fludarabine in treating lupus nephritis (kidney inflammation).
- Conditions
- Glomerulonephritis, Lupus Nephritis, Systemic Lupus Erythematosus
- Trial name
- NCT00001676
- Testing
- SQ Fludarabine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Breast Neoplasms, Prostate Cancer
Evaluation of the Cryotherapy in the Prevention of Nails Toxicity Induced by Taxotere® in Breast or Prostate Cancer
Taxotere® can induce nails changes like dyschromia, hematoma, lines of Beau-Reil (signing the stop of the epithelial proliferation), abscess, or pain.
- Conditions
- Breast Neoplasms, Prostate Cancer, Nail Diseases
- Trial name
- CRYO1 (NCT00925418)
- Testing
- Frozen Glove
- Where
- France
- Volunteers
- 168 people
- Sponsor
- Institut Paoli-Calmettes
Breast Cancer
This Study Investigates the Impact of Single Nucleotide Polymorphisms in Genes Involved in the Pharmacokinetics and Toxicity of Doxorubicin (DOX) in Egyptian Female Patients with Breast Cancer. It Also Aims to Explore the Association of Pretreatment Neutrophil to Lymphocyte Ratio to PCR
This study aims to investigate the effect of single nucleotide polymorphisms (SNPs) of genes involved in doxorubicin transport and metabolism on its pharmacokinetics and toxicity in Egyptian breast cancer patients.
- Trial name
- NCT06595758
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Menoufia University
Radiodermatitis, Radiation Toxicity
Efficacy of the Mepitel® Film on the Prevention of Radiodermatitis in the Inguinal Fold.
The aim is to quantify the efficiency of the Safetac product Mepitel® Film on the prevention of radiodermatitis for cancer patients treated with external beam radiation therapy near the inguinal fold(s).
- Conditions
- Radiodermatitis, Radiation Toxicity, Radiotherapy Side Effect
- Trial name
- NCT04617730
- Testing
- Mepitel® film, Flamigel®
- Volunteers
- 35 people
- Sponsor
- Jules Bordet Institute
Breast Cancer, Cardiac Toxicity
BreAst Cancer and Cardiotoxicity Induced by RAdioTherapy: the BACCARAT Study
Breast radiotherapy RT used until the 1990s was clearly responsible for increased mortality due to long term cardiac complications.
- Trial name
- BACCARAT (NCT02605512)
- Testing
- Subclinical cardiac lesions and biomarkers
- Where
- France
- Volunteers
- 118 people
- Sponsor
- Sophie JACOB
Invasive Ductal Breast Carcinoma, Invasive Ductal Carcinoma, Breast
Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer
The purpose of this study is to determine if the dose of radiation therapy that is effective in producing a treatment response, delivered over a shorter treatment period, is a safe approach that causes few or mild side effects in…
- Conditions
- Invasive Ductal Breast Carcinoma, Invasive Ductal Carcinoma, Breast, DCIS, DCIS Grade 1
- Trial name
- NCT04084730
- Testing
- Accelerated Partial Breast Irradiation
- Where
- 9 sites in United States
- Volunteers
- 280 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer
Early Cardiac Toxicity of Adjuvant CT in Elderly BC.
The primary objective is to evaluate the difference in cardiac strain rate evolution in elderly early BC patients treated with (neo) adjuvant anthracycline-based chemotherapy compared with a non-anthracycline regimen…
- Trial name
- NCT01301040
- Testing
- epirubicin, cyclophosphamide, docetaxel
- Where
- Belgium
- Volunteers
- 2 people
- Sponsor
- Jules Bordet Institute
Radiation Dermatitis
M-PART in Head and Neck Cancer Patients Treated With KeraStat Cream for Acute Radiation Dermatitis
The purpose of this research study is to test the ability of a mobile device application (MyCap) to collect patient information about their radiation skin rash in patients with head and neck cancer being treated with radiation…
- Trial name
- NCT06441266
- Testing
- KeraStat cream, M-PART Assessments via MyCap, Clinical Assessments
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Wake Forest University Health Sciences